Exagen
NASDAQ: XGNVista, US · Delaware corporation · 7 known investors
Exagen develops diagnostic and monitoring tests for autoimmune diseases, including tools to distinguish connective tissue disease and assess lupus prognosis and progression. The company serves healthcare professionals and patients with chronic autoimmune conditions.
BiotechDigital HealthHealthtechMedical Devices
Founders & leadership
TD
Thierry DervieuxExecutive
WS
Wendy SwedickExecutive
FR
Fortunato R. RoccaExecutive
SR
Sam RiccitelliNamed on SEC filing
CL
Curt LaBelleNamed on SEC filing
MW
Michael WalshNamed on SEC filing
BP
Beto PallaresNamed on SEC filing
Board
JL
BB
EP
Ebetuel PallaresBoard director
AW
Arthur WeinsteinBoard director
JM
John M. RadakBoard director
Investors · 7
Reported raises · per SEC filings
Form D private placements$48.8M disclosed across 15 rounds · 2014–2019
▶$6.6MraisedFeb 2019 · 4 investors · BiotechnologyRule 506(b)
▶$6.6MraisedFeb 2019 · 4 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Daniel C. BurrellDirector
- Thierry DervieuxExecutive Officer
- Fortunato R. RoccaExecutive Officer, Director
- Ebetuel PallaresDirector
- James L.L. TullisDirector
- Kamal AdawiExecutive Officer
- Arthur WeinsteinDirector
- Brian BirkDirector
- Offering amount
- $16M
- Amount sold
- $6.6M
- First sale
- Jan 2019
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$3.7MraisedMay 2017 · 4 investors · BiotechnologyRule 506(b)
▶$3.7MraisedMay 2017 · 4 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- James L.L. TullisDirector
- Mark HazeltineExecutive Officer
- Fortunato R. RoccaExecutive Officer, Director
- Ebetuel PallaresDirector
- Frank WitneyDirector
- John M. RadakDirector
- Thierry DervieuxExecutive Officer
- Arthur WeinsteinDirector
- Brian BirkDirector
- Offering amount
- $13.2M
- Amount sold
- $3.7M
- First sale
- May 2017
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$1.3MraisedApr 2017 · 5 investors · BiotechnologyRule 506(b)
▶$1.3MraisedApr 2017 · 5 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Ebetuel PallaresDirector
- James L.L. TullisDirector
- Brian BirkDirector
- Wendy SwedickExecutive Officer
- Thierry DervieuxExecutive Officer
- John M. RadakDirector
- Frank WitneyDirector
- Fortunato R. RoccaExecutive Officer, Director
- Arthur WeinsteinDirector
- Offering amount
- $1.3M
- Amount sold
- $1.3M
- First sale
- Apr 2017
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$1.5MraisedMar 2017 · 4 investors · BiotechnologyRule 506(b)
▶$1.5MraisedMar 2017 · 4 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Ebetuel PallaresDirector
- Brian BirkDirector
- Thierry DervieuxExecutive Officer
- John M. RadakDirector
- Wendy SwedickExecutive Officer
- Arthur WeinsteinDirector
- Frank WitneyDirector
- Fortunato R. RoccaExecutive Officer, Director
- James L.L. TullisDirector
- Offering amount
- $1.5M
- Amount sold
- $1.5M
- First sale
- Feb 2017
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$995.9KraisedFeb 2017 · 4 investors · BiotechnologyRule 506(b)
▶$995.9KraisedFeb 2017 · 4 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Wendy SwedickExecutive Officer
- James L.L. TullisDirector
- Arthur WeinsteinDirector
- Fortunato R. RoccaExecutive Officer, Director
- Ebetuel PallaresDirector
- Thierry DervieuxExecutive Officer
- John M. RadakDirector
- Frank WitneyDirector
- Brian BirkDirector
- Offering amount
- $995.9K
- Amount sold
- $995.9K
- First sale
- Jan 2017
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$995.9KraisedDec 2016 · 4 investors · BiotechnologyRule 506(b)
▶$995.9KraisedDec 2016 · 4 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- James L.L. TullisDirector
- Ebetuel PallaresDirector
- Wendy SwedickExecutive Officer
- Brian BirkDirector
- Fortunato R. RoccaExecutive Officer, Director
- Frank WitneyDirector
- Arthur WeinsteinDirector
- Thierry DervieuxExecutive Officer
- John M. RadakDirector
- Offering amount
- $995.9K
- Amount sold
- $995.9K
- First sale
- Dec 2016
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$995.9KraisedNov 2016 · 4 investors · BiotechnologyRule 506(b)
▶$995.9KraisedNov 2016 · 4 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Frank WitneyDirector
- Brian BirkDirector
- Ebetuel PallaresDirector
- James L.L. TullisDirector
- Arthur WeinsteinDirector
- Fortunato R. RoccaExecutive Officer, Director
- Thierry DervieuxExecutive Officer
- Wendy SwedickExecutive Officer
- John M. RadakDirector
- Offering amount
- $995.9K
- Amount sold
- $995.9K
- First sale
- Nov 2016
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$995.9KraisedOct 2016 · 4 investors · BiotechnologyRule 506(b)
▶$995.9KraisedOct 2016 · 4 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Thierry DervieuxExecutive Officer
- Wendy SwedickExecutive Officer
- Arthur WeinsteinDirector
- James L.L. TullisDirector
- Fortunato R. RoccaExecutive Officer, Director
- John M. RadakDirector
- Brian BirkDirector
- Ebetuel PallaresDirector
- Frank WitneyDirector
- Offering amount
- $995.9K
- Amount sold
- $995.9K
- First sale
- Oct 2016
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Competitors · 4
by search overlapQuest Diagnostics73 shared keywordsQuest Diagnostics is the world's leading provider of diagnostic information services, serving one in three adult Americans and half of US physicians and hospitals. The company offers diagnostic insights and testing services to consumers and healthcare providers to support health decision-making.
Labcorp72 shared keywordsLabcorp provides clinical laboratory testing, diagnostics, and lab data services for patients, healthcare providers, and biopharma companies, including genetic health panels, oncology testing, and self-ordered lab tests. It also offers AI-powered tools such as a results-explaining consumer app, a diagnostic assistant integrated into EHRs, and a laboratory data analytics platform to support drug development and clinical research.
Ideagen53 shared keywordsIdeagen provides compliance and risk management software for regulated industries including aviation, life sciences, and food. The platform helps organizations in high-compliance sectors manage processes, people, and product safety.
Nivagen40 shared keywordsNivagen is a specialty pharmaceutical company that develops, manufactures, and markets generic and specialty drugs including sterile injectables and 505(b)(2) products, operating manufacturing facilities in California, Europe, and Japan. The company provides contract development and manufacturing (CDMO) services including custom drug product development, out-licensing, and 503B compounding services for institutional channels.
Companies competing with Exagen for the same Google search keywords, organic and paid, via search-intersection analysis.
In the news
Frequently asked questions
- What does Exagen do?
- Exagen develops diagnostic and monitoring tests for autoimmune diseases, including tools to distinguish connective tissue disease and assess lupus prognosis and progression. The company serves healthcare professionals and patients with chronic autoimmune conditions.
- Who are Exagen's investors?
- Exagen's investors include Cottonwood Technology Fund, EPIC VENTURES, H.I.G. Capital, H.I.G. HealthBridge Partners, Sun Mountain Capital, Tullis Health Investors, Tullis.
- How much funding has Exagen raised?
- Exagen has disclosed $48.8M raised across 15 rounds.
- Where is Exagen headquartered?
- Exagen is headquartered in Vista, US.